Result of Annual General Meeting
Source: RNS![](https://tracker.live.rns-distribution.com/track.live-rns/5279991_d9353a075fe0b610698e373da828b7e4.png)
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or the "Company")
Result of Annual General Meeting
Alderley Park, 24 July 2024 - BiVictriX Therapeutics plc (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst reducing treatment-related toxicities, announces that at the Company's Annual General Meeting held today at 3:00 pm at the Company's registered office, Mereside Alderley Park, Alderley Edge, Manchester SK10 4TG, all resolutions were duly passed.
Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 25th June 2024.
Details of proxy votes received prior to the meeting will be made available on the Company's website at https://bivictrix.com/investor-relations/.
The proxy results were as follows:
RESOLUTION NUMBER |
VOTES FOR |
VOTES AGAINST |
VOTES WITHELD |
TOTAL VOTES |
1 |
10,739,609 |
0 |
0 |
10,739,609 |
2 |
10,739,609 |
0 |
0 |
10,739,609 |
2 |
10,057,109 |
682,500 |
0 |
10,739,609 |
4 |
10,057,109 |
682,500 |
0 |
10,739,609 |
5 |
10,064,609 |
675,000 |
0 |
10,739,609 |
6 |
10,064,609 |
675,000 |
0 |
10,739,609 |
ENDS
For more information, please contact:
|
|
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.
The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.
BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.